Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Moodys
QuintilesIMS
Healthtrust
Harvard Business School
Baxter
Chinese Patent Office
Chubb
Fish and Richardson

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,037,529

« Back to Dashboard

Which drugs does patent 7,037,529 protect, and when does it expire?

Patent 7,037,529 protects TRICOR and is included in two NDAs.

This patent has eighty-five patent family members in thirty-six countries.
Summary for Patent: 7,037,529
Title:Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
Abstract:The invention provides an immediate-release fenofibrate composition comprising (a) an inert hydrosoluble carrier covered with at least one layer containing fenofibrate in a micronized form having a size less than 20 .mu.m, a hydrophilic polymer and, optionally, a surfactant, the polymer making up at least 20% by weight of (a); and (b) optionally one or several outer phase(s) or layer(s).The invention also provides a method for preparing said composition.
Inventor(s): Stamm; Andre (Griesheim, FR), Seth; Pawan (Irvine, CA)
Assignee: Laboratoires Fournier (Dijon, FR)
Application Number:09/899,026
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Process; Use;

Drugs Protected by US Patent 7,037,529

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-002 Nov 5, 2004 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie Inc TRICOR fenofibrate TABLET;ORAL 021203-001 Sep 4, 2001 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie Inc TRICOR fenofibrate TABLET;ORAL 021203-003 Sep 4, 2001 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,037,529

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France97 00479Jan 17, 1997

Non-Orange Book US Patents Family Members for Patent 7,037,529

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,329,214 Process for producing fenofibrate tablets ➤ Try a Free Trial
6,589,552 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it ➤ Try a Free Trial
6,596,317 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it ➤ Try a Free Trial
6,074,670 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,037,529

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 011411 ➤ Try a Free Trial
Austria 233556 ➤ Try a Free Trial
Austria 291911 ➤ Try a Free Trial
Austria 307576 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Mallinckrodt
McKesson
Federal Trade Commission
Healthtrust
Covington
Farmers Insurance
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.